Mind Medicine (MindMed) Inc. Completes $28.75 Million Bought Deal Prospectus Offering

October 30, 2020

Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and experiential therapies to address addiction and mental illness, completed a bought deal prospectus offering of 27,381,500 units for aggregate gross proceeds of $28,750,575. The offering was led by Canaccord Genuity Corp. as sole bookrunner and underwriter.

Wildeboer Dellelce LLP acted for MindMed in connection with the offering with a team comprised of Perry Dellelce, Peter Volk, Rebecca Cochrane and Katie Drury (corporate/securities) and Katy Pitch and Marija Tasevska (tax).